Lacrecia J Britton1, Gabriela R Oates2, Robert A Oster2, Staci T Self3, Robert B Troxler3, Wynton C Hoover3, Hector H Gutierrez3, William T Harris4. 1. Children's of Alabama Cystic Fibrosis Center, Birmingham, Alabama. 2. Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama. 3. Division of Pediatric Pulmonology, University of Alabama at Birmingham, Birmingham, Alabama. 4. Division of Pediatric Pulmonology, University of Alabama at Birmingham, Birmingham, Alabama. tharris@peds.uab.edu.
Abstract
OBJECTIVE: The clinical benefit of newborn screening (NBS) for cystic fibrosis (CF) has been primarily nutritional, with less overt respiratory impact. Identification of risk factors for infant CF lung disease could facilitate targeted interventions to improve pulmonary outcomes. METHODS: This retrospective study evaluated socioeconomic information, clinical data, and results from routine infant pulmonary function testing (iPFT) of infants diagnosed with CF through NBS (N = 43) at a single CF center over a 4-year period (2008-2012). A five-item composite clinical score was developed and combined with socioeconomic indicators to facilitate identification of CF infants at increased risk of early-onset respiratory impairment. RESULTS: Paternal education was positively associated with lung function (P = 0.02). Clinical score <7 (on a scale of 0-10) predicted diminished pulmonary measure (P < 0.005). Retrospective risk stratification by clinical score and paternal education identified CF infants at low, intermediate, or high risk of pulmonary disease. Forced expiratory volume (FEV0.5 %, mean ± SD) averaged 115 ± 19% in the low-risk group, 97 ± 17% in the intermediate-risk group, and 90 ± 8% in the high-risk group (P < 0.005). Results were similar for mid-expiratory flows (FEF25-75 %). Multiple regression analysis confirmed the predictive value of this risk stratification model of CF infant pulmonary health. CONCLUSION: We combined socioeconomic and clinical data to risk-stratify CF infants for early-onset lung disease as quantified by iPFT. Our model showed significant differences in infant pulmonary function across risk groups. The developed tool offers an easily available, inexpensive, and non-invasive way to assess risk of respiratory decline in CF infants and identify those meriting targeted therapeutic attention. Pediatr Pulmonol. 2016;51:1168-1176.
OBJECTIVE: The clinical benefit of newborn screening (NBS) for cystic fibrosis (CF) has been primarily nutritional, with less overt respiratory impact. Identification of risk factors for infantCF lung disease could facilitate targeted interventions to improve pulmonary outcomes. METHODS: This retrospective study evaluated socioeconomic information, clinical data, and results from routine infant pulmonary function testing (iPFT) of infants diagnosed with CF through NBS (N = 43) at a single CF center over a 4-year period (2008-2012). A five-item composite clinical score was developed and combined with socioeconomic indicators to facilitate identification of CF infants at increased risk of early-onset respiratory impairment. RESULTS: Paternal education was positively associated with lung function (P = 0.02). Clinical score <7 (on a scale of 0-10) predicted diminished pulmonary measure (P < 0.005). Retrospective risk stratification by clinical score and paternal education identified CF infants at low, intermediate, or high risk of pulmonary disease. Forced expiratory volume (FEV0.5 %, mean ± SD) averaged 115 ± 19% in the low-risk group, 97 ± 17% in the intermediate-risk group, and 90 ± 8% in the high-risk group (P < 0.005). Results were similar for mid-expiratory flows (FEF25-75 %). Multiple regression analysis confirmed the predictive value of this risk stratification model of CF infant pulmonary health. CONCLUSION: We combined socioeconomic and clinical data to risk-stratify CF infants for early-onset lung disease as quantified by iPFT. Our model showed significant differences in infant pulmonary function across risk groups. The developed tool offers an easily available, inexpensive, and non-invasive way to assess risk of respiratory decline in CF infants and identify those meriting targeted therapeutic attention. Pediatr Pulmonol. 2016;51:1168-1176.
Authors: Robin S Everhart; Barbara H Fiese; Joshua M Smyth; Adrienne Borschuk; Ran D Anbar Journal: Pediatr Allergy Immunol Pulmonol Date: 2014-06-01 Impact factor: 1.349
Authors: Barry M Linnane; Graham L Hall; Gary Nolan; Siobhan Brennan; Stephen M Stick; Peter D Sly; Colin F Robertson; Philip J Robinson; Peter J Franklin; Stephen W Turner; Sarath C Ranganathan Journal: Am J Respir Crit Care Med Date: 2008-09-11 Impact factor: 21.405
Authors: Peter D Sly; Siobhain Brennan; Catherine Gangell; Nicholas de Klerk; Conor Murray; Lauren Mott; Stephen M Stick; Philip J Robinson; Colin F Robertson; Sarath C Ranganathan Journal: Am J Respir Crit Care Med Date: 2009-04-16 Impact factor: 21.405
Authors: Don B Sanders; Zhanhai Li; Anita Laxova; Michael J Rock; Hara Levy; Jannette Collins; Claude Ferec; Philip M Farrell Journal: Ann Am Thorac Soc Date: 2014-01
Authors: David C Taylor-Robinson; Rosalind L Smyth; Peter J Diggle; Margaret Whitehead Journal: Lancet Respir Med Date: 2013-01-30 Impact factor: 30.700
Authors: Gabriela R Oates; Elizabeth Baker; Steven M Rowe; Hector H Gutierrez; Michael S Schechter; Wayne Morgan; William T Harris Journal: J Cyst Fibros Date: 2020-02-17 Impact factor: 5.482
Authors: Heather N Muston; James E Slaven; Christina Tiller; Charles Clem; Thomas W Ferkol; Sarath Ranganathan; Stephanie D Davis; Clement L Ren Journal: Pediatr Pulmonol Date: 2021-06-23